scholarly journals Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Blood ◽  
2017 ◽  
Vol 130 (6) ◽  
pp. 732-741 ◽  
Author(s):  
Michael D. Amatangelo ◽  
Lynn Quek ◽  
Alan Shih ◽  
Eytan M. Stein ◽  
Mikhail Roshal ◽  
...  

Key Points Enasidenib inhibits mIDH2, leading to leukemic cell differentiation with emergence of functional mIDH2 neutrophils in rrAML patients. RAS pathway mutations and increased mutational burden overall are associated with a decreased response rate to mIDH2 inhibition.

Blood ◽  
2017 ◽  
Vol 129 (18) ◽  
pp. 2493-2506 ◽  
Author(s):  
Cécile Naudin ◽  
Aurore Hattabi ◽  
Fabio Michelet ◽  
Ayda Miri-Nezhad ◽  
Aissa Benyoucef ◽  
...  

Key Points The RNA regulators PUMILIO sustain HSPC and acute myeloid leukemia cell growth by upregulating FOXP1 expression through direct binding to 2 FOXP1-3′UTR PUMILIO-binding elements. FOXP1 mediates PUMILIO growth-promoting activities by repressing expression of p21CIP1 and p27KIP1cell cycle inhibitors.


Oncotarget ◽  
2016 ◽  
Vol 7 (47) ◽  
pp. 78095-78109 ◽  
Author(s):  
Xiaohui Si ◽  
Xiaoyun Zhang ◽  
Xing Hao ◽  
Yunan Li ◽  
Zizhen Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document